Data From Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting
SAN DIEGO, June 6 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week...
Boehringer Ingelheim’s lead investigational oncology compound BIBW 2992 demonstrates potential as a next generation treatment for non-small cell lung cancer and head and neck cancer
May 21, 2010 12:00 AM Eastern Daylight Time
Further new data on BIBW 2992* suggests it is at least as effective as cetuximab in head-and-neck cancer, and reaffirms activity in non-small-cell lung cancer with EGFR mutations
Rosetta Genomics will introduce its first microarray-based diagnostic — a test to identify cancers of unknown primary origin — through its Clinical Laboratory Improvement Acts-compliant facility in Philadelphia during the second half of the year, according to the firm's highest official.
President and CEO Kenneth Berlin said recently that the next-generation version of Rosetta's miRview Mets test will run on an array...
ScienceDaily (Jan. 12, 2010) — A combined positron emission tomography-computed tomography (PET-CT) scan of the whole body appears to detect cancer in individuals with related neurologic complications more accurately than some other commonly used tests, according to a report posted online that will appear in the March print issue of Archives of Neurology, one of the JAMA/Archives journals.
Paraneoplastic neurologic disorders occur in some people with cancer -- including lung, breast...
Oncology Social Workers Report 'Uncertain' and 'Unknown' Cancers Significantly Increase Patient Distress
- Survey of AOSW Members Highlights Need for Resources, Education, Better Diagnostic Tools to Reduce Psychological Impact of Unknown Cancer Diagnoses -
SAVANNAH, Ga., May 6 /PRNewswire/ -- Cancer patients whose primary cancer type is "uncertain" or "unknown" may experience more distress than patients whose primary cancer is definitively diagnosed,...
